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SUMMARY
19 pat'cllts wp~e selected, from the patients screened, for investigation
within 48 h0U~S of the onset of an ischaemic cerebrovascular accident.
Clinical neurulogical scoring, computerized tomography lCT) scans and
single photon emission computed tomography (SPECT) scans were performed
on day 1, day 10 and day 30.
SPECT scan data was analysed by 5 semi-quantitative methuds, and
findings were compared with neuroloyical clinical scores on each
respective day.
It was found that day 1 SPECT scans are of value for early localization
of the acute ischaemic infarction.
A multiple regression model was developed using both the day 30 Defect
Volume index and segmental analysis score which related to the day 30
clinical scores. The day 1 model was unsatisfactory and no such model
was found relating day 10 SPEcr semi-quantitative methods to day 10
clinical scoring. Changes in semi-quantitative scores from day 1 to day
30 did not correlate with clinical changes. Longer follow up may be
required for there to be value in performing SPECr scans in stroke
trials.
A prognostic equation was derived by multiple regression analysis of day
1 SPECT scan scores and day 30 clinical scores.
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CHAPTER 1
INTRODUCTION
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"Stroke" is a term used to describe any sudden paralysis resulting from
a vascular disturbance in the brain due, most commonly, to thrombosis,
embolism or haemorrhage (1, 2).
The importance of stroke and it's complications is demonstrated by the
fact that it is the third hiqhest cause of death (in adults) in North
America and causes even more physical disability which is expensive for
both the state and the individual (3, 4, 5). Rehabilitation of stroke
patients can be highly labour intensive and so resources should be
applied to those most likely to derive maximum benefit from such therapy
(6).
Early localization and definition of stroke pathology is advised because
of the value of various therapeutic measures, such as anticoagulant
therapy in progressing stroke, surgical intervention with endar terectoey
and extracranial-intracranial bypass surgery (4, 7, 8, 9, 10). Based on
the timing of maximum cerebral oedema (i.e. 2 to 4 days post-ictus)
medical therapy aimed at minimizing the amount of infarction should be
started within 24 to 48 hours of the ischaemic event (11).
Computerized axial tomography (CT scan) and magnetic resonance imaging
(MRI) both play an important role in the diagnosis of cerebrovascular
disease (12, 13), but functional studies should be considered so as to
better understand the pathophysiologic basis of stroke evolution. CT
scans may often be negative in the first 24 to 48 hours after the acute
onset of cerebral infarction (14, 15, 16, 17), whereas single photon
emission tomography (SPECT) with cerebral perfusion agents and MRI are
usually positive at tnis time (14, 18, 19, 20).
- 2 -
Interventional treatment could be mora fully evaluated follow:ng
functional studies, while cerebral perfusion i~aging may also have a
place in determining the therapeutic value of such treatment,
particularly in regard to objective c~;, ica1 stroke trials (8, 21),
Essential to the ~Jnagement of acute stroke is the knowledge of whether
the involved brain tissue is reversibly or irreversibly damaged (12,
22). Early restoration of blood flow in acute troke patients may
improve recovery, especially in the ischaemic penumbra (peri-infarct
area) (23, 24). Any interventional therapeutic study in acute brain
infarction is based on the assumption that the ischaemic insult is
reversible in some of the affected neurons.
Physiological patterns that characteri~e viable tissue may be identified
by correlating acute changes in cerebral blood flow and metabolism with
the clinical course of the patient. Therapeutic measures that alter
impaired tissue function and subsequently improve clinical outcome or
shorteil hospital stay may then be investigated (25).
POSl+ron emission tomography (PET) may be used for investigating the
change~ in cerebral oxygen metabolic rate and glucose utilization, which
accompany changes in structural brain neuronal function (12, 25, 26,
27). .PLT is, however, expensive and is limited to a tew research
centres, ~lthough it permits reliable quantitative m1asurements of
cerebral pnysiology over a wide range of circumstances (27, 28). In
more qenera l use, SPECT imaging may demonstrate regiona 1 cer-ebr-a 1 blood
flow change~ seen in acute ischaemic cerebral infarction.
Several lipophilic cerebral perfusion agents that cross the normal
blood-brain barrier to produce tomographic blood flow maps hale been
produced. In current use for this purpose are IodineQ123
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iodoamphetamine (8, 17, 20, 29, 3D, 31, 32), Iodine-123 propanediamine
(HIPDM) (29, 3D, 33), Thallium-201 diethyl dithio-carbamate (3D, 31, 34.
35), Technetium-99m DMG-ZMP (a toro~ic acid adduct of technetium oxime,
SQ 32 097) (36, 37), Technetium-99m amino-alkyl diamin0dithiol
derivatives such as NEP-DADT (38), Technetium ethyl cysteinate dimer
(39, 40, 41, 42, 43, 44, 45, 46, 47, 48) and Technetium hexa-methyl
propylene amine oxime (21, 49, 50, 51).
Xenon-133 has been used for the measurement of cerebral perfusion but
purpose built equipment is required. The 81 KeV photon emitted makes
the discrimination of scattered radiation a problem, yielding poor
spatial resolution and considerable crosstalk from background
radioactivity (12, 3D, 32).
Objective comparison of serial SPECT scans performed in order to
evaluate therapeutic. measures and possibly to develop a prognostic index
for acute ischaemic infarction would be facilitated by a reliable
semi-quantitative method to determine cerebral blood flow changes. The
various analytical techniques of evaluation of cerebral blood flow
changes in ac~te ischaemic infarction should, therefore, be correlated
with a selected clinical scoring system (the Cdnadian Neurological scale
being used in this thesis),
Predicting the functional outcome following a stroke remains a problem
to which there is not yet a satisfactory solution. Clinical prognostic
indicators have not proved usefu1 and are only used to describe in
general terms those patients that will imp~ove or deteriorate (6). The
improvement of prognostic assessment in cerebrovascular disease is
urgently required (52).
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In thls thesis an attempt has been made to determine whether clinical
outcome can be predicted (ly in the course of the ischaemic infarction
by using tb8 semi-quantification of the decrease in regional cerebral
blood flow fCJnd in this pathology. Five methods of semi-Quant fication
of regional cerebral blood flow defects ~ere investigated, in patients
presenting with acute ischaemic infarctlon. An assessment of the role
of cerebral ~_rfusion imaging with Technetium-99m Hexa-methyl propylene
amine oxime (HMPAO) in clinical stroke manage~ent was undertaken.
In this pilot study of 19 patients, (who met the trial criteria, out of
more than 100 patients screened) only trends and suggestions for further
study could be deduced. Other centres have had sil~ilarproblems in
recruiting into acute stroke trials, using only 7,4 - 10,2% cf patients
screened (53).
- 5 -
CHAPTFR 2
OBJECTIVES
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OB,lEeTI VES
The aims of this thesis are as follows:~
1. To de tr rnrine the place of SPEeT cerebral perfusion studies in
the mAnagement of cerebral infarction, and hence their value in
stroke ti'ia1s.
2. To investigate five methods of semi-quantification of cerebral
perfusion lesions in acute ischaemic cerebral infarction and to
determi ne wh ich, if any, of these methods carre 1ates wi th
clinical findings and would be of clinical value.
The methods of semi-quantification investigated wer~ :-
i) Defect volume index (DV index) as described by Launes et
al (24).
'ii) Side to side comparative region of interest (ROI) ratios
based on counts/voxel seen in a small area (33, 35, 54,
55).
iii) Comparison of counts/voxel of a small area in the affected
region to thp. counts/pixel in the ipsilateral cerebellum,
expressed as a percentage (56, 51).
;v) Thirty degree segmental analysis of the average counts per
segment (8, 58).
vj The area of the lesion as compared with the ared of the
ipsilateral cerebral hemispheric area expressed as a
percentage.
3. To determine whether there is any prognostic value in the use of
semi-quantification of cerebral perfusion defects with regard to
stroke manag~ment.
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CHAPTER 3
PATIENTS, MATERIALS AND METHODS
A. PATIENT POPULATION
- INCLUSION CRITERIA
- EXCLUSION CRITERIA
B. RADIOPHARMACEUTICAL
C. CT SCANS
D. SPECT SCANS
E. VISUAL ANALYSIS
F. SEMI-QUANTITATIVE ANALYSIS OF SP~CT SCANS
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PATIENTS, MATERIALS AND MUHO~
A. QATIENT POPULATION
Nineteen patients presenting with an acute ischaemic cerebral infarct
were selected from more than one hundred acute stroke patients
investigated at the Johannesburg hospital, over a two year period, for
entry into the study.
INCLUSION CRITERIA
1. Caucasian patients between the ages of 45 to 80 years presenting
with an occlusive cerebrovascular accident (CVA) within a
maximum of 48 hours of the vent.
2. Patients with a previous acute cerebrovascular accident were
only included if no consequent motor or intellectual deficit or
sequelae remained following that previous incident.
EXCLUSION CRITERIA
1, Any patient where there was full recovery within 72 hours. This
was to exclude any spontaneous clinical evolution or other
pathology such as a transient ischaemic a~tack.
2. Patients with reversible ischaemic neurological deficit (RIND)
were excluded when the dlagnosis had been established (either on
day 1, or on day 10 having confirmed RIND using the CT scan),
3. Cerebral or subarachnoid haemorrhage (excluded by CT scan on day
1) .
4. Patients presenting in a stage IV coma.
5. Patients with a CVA of other vascular origin (e.g. aneurysm,
vertebro-basilar CVA), or post-traumatic CVA.
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6. Tumours involving the brain or other sites.
7. Degenerative disease of the eNS such as Huntingtons disease,
Parkinsons or Alzheimers disease.
8. Severely psychotic patients on previous or current treatment with
antidepressants or neuroleptics.
9. Severe associated medical problems such as serious cardiac,
renal, hepatic, respiratory dysfunction or severe psychosis.
Patient ages ranged from 51 years to 77 years with a mean age of 65
years. Nine males and ten females were included. The distribution of
cerebral ischaemic infar~ts was as follows :-
9 right middle cerebral artery territory lesions.
1 right anterior cerebral artery territory lesion.
right posterior cerebral artery territory lesion.
1 pdtient with multiple small infarcts as confirmed with
MRI although Glinically presented with left middle
cerebral artery pathology.
7 left middle cerebral artery territory lesions (one of
which was lacunar in nature and one with a small lesio~
In the left posterior internal capsule).
See Fig 1.
Two patients died during the trial period, that is, on day 4 and on day
23 (frcm unrelated problems). One patient had another cerebrovascular
accident on day 19.
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FIG. 1 PATIENT CHARACTERISTICS
PATIENT
NO. AGE SEX SITE OF LESION OTHER
56 M Right MCA Died on day 4
2 74 F Multiple small infarcts Clinically Right MCA
3 55 F Right MeA
4 61 M Left MCA
5 69 M Left MCA Posterior left
internal capsule
6 69 M. Left MCA Small lacunar infarct
7 71 F Left MCA
8 72 F Left MCA
9 65 M Right MCA Repeat CVA day 19
10 58 F Right MeA.
11 74 M Right MCA Died day 23
12 53 M Right PCA
13 51 M Left MCA
14 67 M Right MeA
15 63 F Left MCA
16 76 F Right ACA
17 52 F Right MCA
18 77 F Right MCA
19 73 F Right MCA
ACA Anterior cerebral artery territory
MCA Middle cerebral art.ery territory
peA Posterior cerebral artery territory
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B. RADIOPHARMACEUTICAL
The radiopharmaceutical used for this study was Technetium-99m
hexa-methyl propylene amine oxime (HMPAO) which is a lipophilic cereb.al
perfusion agent that crosses the normal blood br~in barrier.
HMPAO was supplied in single dose vials by Amersham Corporation Each
vial was reconstituted with 500 MBq of Technetium-99m in 5ml of normal
saline, and the total injected intravenously within half an hour of
preparation. This was repeated for each scan.
C. CT SCANS
CT scans were performed on day one in every case, and on days ten and
thirty where possible, in order to verify brain infarction and to
exclude intra-cranial haemorrhage. Both pre- and post-contrast (Conrav
420) injection scans were performed using a Phillips 310 Tomoscar.ner.
D. SPECT SCANS
SPECT scans were performed on days one, ten and thirty (where possible)
after the acute onset of cerebral infarction using an Elscint Apex-415
ECT gamma camera fitted with a general, all-purpose, low energy parallel
hole collimator and a dedicated computer. The ~atients eyes were
shielded, with only the hum of the equipment remaining as background
noise.
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Cerebral SPECT scans were performed twenty minutes after the
injection of 500 MBq of Tc-g9m HMPAO. The data was acquired using a 360
degrees rotation, and an angle step of two degrees (180 projections),
over a period of 20 minutes. A matrix size of 64 x 64 pixels was used.
The raw data was normalized so as to correct for imperfections in the
acquired data, such as, flood non-uniformity, centre of rotation
misalignment, and decay of the radiopharmaceutical between the start and
elidof the SPECT acquisition.
Transaxial images of the normalized raw data was reconstructed by the
standard back projection method. Ramp filtering removed blurring of the
image due to simple back projection, but also increased the noise
present in the projections. The noise factor was reduced by ~he use of
a Hannin0 filter.
A matrix size of 128 X 128 pixels with a zoom factor of two was used to
create eight transaxial slices
hemispheres to the cerebellum.
pixel thickness).
from the superior aspect of the cerebral
Each slice had a thickness of 2,07cm (3
Thinner slices were reconstructed to determine the exact site of the
lesion, if the lesion was not visualized when using a 3 pixel slice
thickness.
The average number of counts obtained per scan was 3,8 megacounts per
scan, while the average count per central slice in the reconstructed
transaxial images was 486 kilocounts.
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Coronal slices were obtained from the transaxial reconstruction, and
displayed from anterior to posterior in the cp.rebral hemispheres with a
slice thickness of 4 pixels on a 64 x 64 matrix.
E. VISUAL ANALYSIS
The area of decreased isotope uptake on the HMPAO SPECT scan was
visually assessed and subjectively scored as being :-
o - not visualized
1 - defect less than 1/4 of the ipsilateral cerebral hemisphere
in size.
2 - 1/4 to 1/2 of the ipsilateral cerebral hemisphere in size.
3 - more than 1/2 of the ipsilateral cerebral hemisphere in
size.
F. SEMI-QUANTITATIVE ANALYSIS OF SPECT SCANS
Once transaxial and coronal images had been reconstructed and stored,
semi-quantitative analysis was performed on each scan.
At the start of this study only the side to side comparisons had been
described. As further methods were reported in literature these were
added to the study, using the same data.
i) Defect Volume index (DV index)
Launes et al in 1989 found that the perfusion defect volume, estimated
from transversal and coronal slices on SPECT scans performed one to
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forty six days after the onset of neurological symptoms of a eVA,
correlated with presenting clinical findings and outcome (24).
In this method the volume of the perfusion defect relative to the brain
volume was measured.
The perfusion defect was identified on the images obtained, and it's
sizd was measured from the transverse and coronal slices in which the
defect appeared largest.
The perfusion defect volume (DV) index was calculated according to the
formula :~
DV = l/L + w/W + h/H
where :-
L = maximal length of the transversal slice in the franta-occipital
projection.
1 = maximal length of the defect in the above slice.
W = maximal width of the transversal slice.
w = maximal width of the defect in the aboye slice.
H maximal height of the supratentorial part of the hrain in the
coronal slice.
r = maximal height of the defect in the above slice.
See fig. 2.
Where no visible defects were seen a DV index of 0 was given. This
method has the advantage that the aecrease in blood flow in the defect
area was not semi-quantitated relative to any brain area that has been
assumed normal.
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C.ORONAL HIAGE
I':IGHT
Fig 2. Method of Defect Volume Measurement
W = width of brain
w = width of the defect
L
LEFT
H
L = length of the brain in the anteroposterior projection
1 = length of the defect
H = height of the brain
h = height of the defect
In this trial the same method was used for subsequent sc~ on days
10 and 30.
ii) Side to side comparison of count density
Small circular regions of interest (ROI) were drawn in the affected area
using the reconstructed transaxial images. A mirror ROI was drawn on
the normal side.
Counts per voxel were determined in the ROI on the assumed normal side
and On the side of the lesion. The counts per voxel of the affected
side were expressed as a percentage of the normal side. The ratio of
count density of the low uptake area relative to the contralateral area
was calculated.
Ratio: count density of low uptake area
--------------------------------------------- x 100%
count density of the contralateral normal side
The same slice and method was used for subsequent scans.
See fig. 3.
This method has been used previously by ~e0nard et al who used five
symmetrical ROIs drawn on two middle tra~sverse slices, to calculate
right to left ratios and to compare HMPAO with I-l~3 HIPDM (33).
Other authors
Buell et al,
54, 59, 60).
have also employed variations of this method, such a~
Podreka et al and Van Royen using the same principle (35,
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Lesion ROI
Fig 3.
~-----------------------
HNTE~:1(IF'
Normal contralateral
ROI
Regions of interest used for side to side
comparison of counts per voxel
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Semi-quantitation of 1-123 IMP SPEcr imaging was obtained by Knapp at
al by side to side comparison of segments containing territories
affected by cerebrovascular disease (61).
Lee et al performed semi-quantitative assessments of region~l cerebral
blood flow defects on 1-123 IMP SPECr images by drawing a region of
interest around the lesion and comparing the count density of the lesion
with that of a simil~r normal contralateral area (62).
iii) Ratio of lesi~n count density to cerebellar count density
A small circular ROI was drawn in the affected area on the transaxial
image where the lesion was most clearly seen. The counts per voxel for
this ROI were obtained.
A similar circular ROI was placed over the ipsilateral cerebellar
hemisphere on the appropriate transaxial image and the count per voxel
for the cerebellum was obtained. The cerebellar hemisphere with the
highest count density was used if diaschisis was present.
The count density in the affect0J area was expressed as a percentage of
the count density of the cerebel~um.
Count aensity of the lesion ROI
-~----~----------~-----------------------~ x 100%
Count density of the cerebellar homisphere
See fig 4.
- 19 -
r--------------
AHTERIOI;~
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a) Lesion region of interest
ANTEr.'lOR
I PO.STERIO~' I
~ <- --. ---. _'.
b) Cerebellar region of interest
Fig 4. Regions of interest selected for the lesion to
Cerebellum ratio method of semi-quantification
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This method has been previously used by Langen et al who expressed the
opinion that the cerebellum represents a homogeneous reference and is a
better reference region than the normal contralateral region (56).
Costa et al also used this method of semi-quantification when
quantifying washout of Technetium-99m HMPAO (63).
The same ratio using rectangular regions of interest of the same size
was utilized by Perani in 16 patients suffering from Alzheimers disease
and in 16 healthy elderly subjects. Left to right count ratios were
also assessed fnr each pair of symmetrical regions of interest (57).
tv) Thirty degree segmental al.~is
A suitable transverse slice was chosen in which the lesion was well
represented. The same slice was taken for analysis from subsequent
scans.
A circular region of interest was drawn around the image selected and
was divided into thirty degree segments. Segmental analysis was
performed, proceeding in a clockwise manner. The average count per
pixel for each segment was calculated and expressed graphically for each
segment using a Hewlett Packard personal computer. The highest count
value was taken to be 100% and the rest of the image was scaled to this
level.
The side to side difference was expressed in percentage points.
Side to side difference = Normal segment count - defect count density
- 21 -
Fig 5.
ANTERIOR
Pi)',1'ERIOR
Circular region of interest selected for the thirty
degree segmental analysis method
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This difference reflected a negative value if the lesion count density
was less than the normal side and a positive value when luxury perfusion
occurred.
See fig. 5.
SPEeT quantification of cerebral ischaemia using early and late 1-123
iodoamphetamine scans was analysed by Maurer et al in 1990. The authors
used quantitation of redistribution of isotope as an objective index of
improved perfusion (8).
v) Area ratio method
The transaxial image where the defect was largest was chosen. The same
image was chosen on subsequent scans.
The area of decreased isotope uptake was delineated with an irregular
ROI, and the area of the lesion determined.
The area of the ipsilateral cerebral hemisphere was ca1culated. The
defect area was expressed as a percentage of the ipsilateral cerebral
hemispheric area.
Area of the defect
---------------------------------- x 100%
Area of the ipsilateral hemisphere
See fig. 6.
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PO'31'ERIOR
l- .,... ....J
a) Lesion area region of interest
AN1'ERIOR
b) Ipsilateral cereb~al hemisphere region of interest
Fig 6. Lesion area to ipsilateral cerebral hemisphere area
ratio method of s1mi-quantification
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G. CLINICAL SCORING
Patients were assessed clinically by means of the Canadian Stroke
assessment system, introduced by Cote at al (64). The Canadian
Neurological Scale was developed to assess conscious stroke patients who
have neurologic deficit or aphasia (64).
The first part of the scale assesses mentation, with levels of
consciousness, orientation and s~ ech of 'importance, while the second
section scores motor function.
See fig. 7.
All patients were evaluated clinically within 48 hours of the acute
onset of neurological symptoms. Daily clinical assessment for a minimum
of 10 days followed, with further examinations on days 20 and 30.
A clinical scoring system was chosen so as to be:-
simple and non-ambiguous.
have a minimum number of grades per modality tested.
relevant fat' modalities most commonly affected in acute strokes.
easy to use.
easy to interpret.
brief.
practical.
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Biochemistry and full blood counts were also monitored on day 1
(baseline), day 10 and on day 30.
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A. CL:NICAL RESULTS
Two deaths occurred over the thirty day trial period. One patient died
on day four due to cerebral infarct extension and the other patient
improved initially to day twenty and then died from cardio-respiratory
complications.
One further patient improved considerably until day twenty and then had
another cerebral infarct on day twenty one in the opposite carotid
territory.
In the fir$t ten day period, eight of eighteen patients improved by a
score of one point or more on the Canadian scale (44,4%).
Fourteen of sixteen patients (87,5%) remalnlng showed an improvement of
more than a score of one over the whole thirty day tricl period. The
patient who restroked dropped by a score of two between days ten and
thirty.
B. CT SCAN RESULTS
On day one 8 of 19 (42%) CT scans were positive as compared to 12 of 15
(80%) on day ten, and 11 of 13 (84,6%) performed on day thirty. These
findings are in accordance with reported literature, where the CT scan
is often negative in the first 24-48 hours after an acute cerebral
infarction, when no structural brain changes may be identified (I, 30,
65).
See fig. 8
6 patients (40%) demonstrated luxury perfusion (post-cQntrast
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enhancement) on day 10 and 2 patients (15,4%) demonstrated this
phenomenon on day 30.
It is difficult to assess the change in lesion size over the thirty day
trial period on CT s:anning as many lesions were not cBen on day one.
A decrease in visual lesion size was noted in 3 patients from day 10 to
day 30.
C. VISU,I\L ANALYSIS SPECT SCANS
19 scan~ were performed on day I, 18 on day 10 and 14 scans on day 30.
The decreased number of scans performed on day 30 was due to
non-compliance of the patients and the death of 2 of the patients.
16 scans (84%) were positive on day I, with the site of the lesion
correlating with clinical features. 6 were large lesions, 3 medium and
7 small lesions.
15 of 18 ~cans (83%) on day 10 were positive. One patient had died on
day 4. 11 scans were unchanged whilst the lesion size had visually
decreased in 4 patients.
On day 3D, 11 uf the 14 scans (78,6%) were positive. Over the 30 day
period of the trial, 5 lesions were unchanged in size, 5 decreased in
size and 1 lesion increased in size. 3 lesions were net seen on SPEeT
scanning and 5 patients did not have day 30 scals due to various
reasons.
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It was noted that all those patients showing a visual decrease in
lesion size were initially size three or large lesions.
D. DEFECT VO_[IJME INDEX
Using the defect volume index (DV index) method of semi-quantitation, 17
of 19 patients (89.5%) had a positive scan on day 1. Negative isotope
scans were found in the patient with multiple small infarcts and in a
patient with an anterior cerebral artery infarct with all the
semi-quantitative methods investigated.
Of 18 patients scanned on day 10, the DV index remained at zero in 2
patients, improved by more than a score of 0,1 (out of 1) in 6,
increased in 6 patients and remained the same (or a change of less than
0,1) in 4 patients.
By day 30, 2 patients still had a DV index of zero, 6 of 14 lesions
improved by more than 0,1 (i.e. decreased in vOlume), and 3 had an
increase in the DV index as compared to day 1 (i.e. lesion volume
increased), and 3 lesions remained unchanged.
CHANGES IN DV INDEX
DAY 1 TO DAY 10 DAY 1 TO DAY 30
LESION NOT SEEN
NO CHANGE
DECREASED INDEX
INCREASED INDEX
2
4
6
6
2
3
6
3
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These changes were in agreement with patients showing clinical changes
in 7 cases to day 10 (38,9%) and in only 4 patients over the 30 day
trial period (28,6%).
E. SIDE TO SIDE COUNT DENSITY COMPARISON
17 of 19 scans were positive on day 1, although 4 of these scans showed
a relative decrease of less than 10% in counts/pixel as compared to the
normal side.
By day 10 a change of more than 1% was seen as an improvement in lesion
count density in 11 patients, and as a worsening in count den~ity in 4
patients. 1 patient showed no change and 2 patients consistently had
negative scans. These changes were in agreement with clinical changes
observed (i,e. improvement, deterioration or no change) from day 1 to
day 10 in 27,8% of cases.
On day 30, an improvement was seen in 7 patients, deterioration in 4 and
no change in relative count density in 1 case. These changes were in
agreement with clinical changes in 27,8% of Cases.
CHANGES IN SIDE TO SIDE COUNTS/VOXEL MEASUREMENT DIFFERENCES
DAY 1 TO DAY 10 DAY 1 TO DAY 30
LESION NOT SEEN
NO CHANGE
IMPROVED COUNT DENSITY
DETERIORATING COUNT DENSITY
2
1
11
4
2
1
7
4
- 33 -
F. LESION COUNT DENSITY TO CEREBELLAR COUNT DENSITY RATIO,
On day 1, a relative lesion count density of less than 95% of the
cerebellar count density was seen in 17 of 19 patients scanned (89,5%).
An improvement in the relative count density of the lesion of more than
1% was seen in 7 patients to day 10. The relative count density got
worse in 5 and remained the same in 4 cases. The lesion was not
detected in 2 patients on day 10. These changes were in agreement with
the trend in clinical change in 8 of 18 patients scanned to day 10
(44%).
By day 30 the relative count densities improved in 8 cases, 4 lesions
decreased in relative count density (i.e. deterioration) and 2 lesions
were not detected. The changes were in agreement with ciinical changes
in 7 of 14 cases (50%).
CHANGES IN LESION TO CEREBELLAR COUNT DENSITY RATIO
DAY 1 TO DAY 10 DAY 1 TO DAY 30
LESION NOT SEEN
NO CHANGE
IMPROVED RATIO
DETERIORATING RATIO
2
4
7
5
2
o
8
4
G. THIRTY DEGREE SEGMENTAL ANALYSIS
On day one, 12 of '19 scans were positive with this semi-quantitative
method, with side to side differences ranging from 4% to 446.
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Improvement was seen in 5 patients (i.e. a decreased difference),
deterioration in 3 (i.e. an increased side to side difference) and no
change in 4 lesions by day 10. 6 lesions were not detected. These
changes were in agreement with clinical progress in 8 of 18 patients
(44%).
By day 30, the lesion was not detected in 5 cases, improved
semi-quantitatively in 5 deteriorated in 3 and remained unchanged in 1
case. ThlS was in agreement with clinical changes in 5 of 14 cases
(35,7%).
CHANGES IN SIDE TO SIDE DIFFERENCE ON SEGMENTAL ANALYS1~
DAY 1 TO DAY 10 DAY 1 TO DAY 30
LESION NOT SEEN 6 5
NO CHANGE 4 1
DECREASED DIFFERENCE 5 5
INCREASED OIFFERENCE 3 3
H. AREA RATIO METHOD
With this semi-quantitative method 17 of 19 patients had a positive scan
on day 1 (89,5%).
On day 10, 2 scans remained negative; the lesion area remained the same
in 3 patients, decreased in size in 6 and got larger in 7 cases (when a
change of more than 1% was used). Thesp changes were in agreement with
clinical score changes in 38,9%.
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By day 30, 2 scans remained negative. The area of the lesion
remJined the same in 1 case, decreased in size by more than 1% in £ and
increased in size in 5 patients. The change in lesion area by day 30
only agreed with 28,6% of clinical changes seen.
CHANGES IN LESION AREA
DAY 1 TO DAY 10 DAY 1 TO DAY 30
LESION NOT SEEN 2 2
NO CHANGE 3 1
DECREASE IN AREA 6 6
INCREASE IN AREA 7 5
I. LUXURY PERFUSION
So~called luxury perfusion as seen with contrast enhancement was seen in
5 pati0nts on day 10, 1 patient on days 10 and 30, and in 1 patient o~
day 30 only, when using CAT scanning.
This luxury perfusion could also be detected on visual inspection of the
SPECT scans in 5 patients on day 10 corresponding to that seen on the
CAT scans.
An increase in count density above 100% (of the normal hemisphere) could
be determined with 3 semi-quant1tative methods, namely the side to side
comparison of count density (4 patients), the lesion to cerebellar count
density ratio method (3 patients), and on segmental analysis of the
transverse image (2 patients).
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J. CROSSED CEREBELLAR DIASCHISIS
Crossed cerebellar diaschisis was present when the count density of the
contralateral cerebellar hemisphere was hypoperfused relative to the
ipsilateral cerebellar hemisphere by a count density of more than 10
counts per pixel. This phenomenon was observed in 74% of patients in
this trial.
K. STATISTICAL ANALYSIS
For statistical purposes results were divided into day 1, day 10 and day
30.
The correlation coefficients for each semi-quantitative method against
clinical scoring were particularly low when all the patients were
included for simple regression analysis i.e.
Range of correlation coefficients
Day 1 range = 0,14 - 0,36
Day 10 range = 0,13 - 0,33
Day 30 range = 0,19 - 0,55
The data was then "cleanedtl on a clinical basis with exclusion of two
patients on days 1 and 10 (with multiple infarcts and with a posterior
cerebral artery territory infarct), and with the exclusion of an
additional patient on day 30 who had restroked on day 19. The
correlation coefficients then changed on days I, 10 and 30 i.e.
Range of correlation coefficients on tlcleaned' data
Day 1 range = 0,36 - 0,52
Day 10
Day 30
range = 0,26 - 0,46
range = 0,20 - 0,77
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The semi-quantitative methods correlat~ ·tell with each other o~ day 1
(p ~ 0,81 - 0,93) and on day 30 (p = 0,34 - 0,92). Poor correlation was
seen on day 10 possibly due to the presence of luxury perfusion
affecting three semi-quantitative methods and possibly due to clinical
changes not adequately reflected on the SPECT scan at this time.
These observations led to the conclusion that the development of a
multiple regression model or models would be the most appropriate way in
whicn to rel~te the clinical score to the semi-quantitative method
scores ,
n
;~
!J
The day 1 data was examined first. It was found by forward stepwise
regression that the only significant semi-quantitative variable was the
thirty deg(ee segmental analysis score, where :~
Day 1 Clinical Scor-e ::6,8 + O,~7.g x day J. segmental analysis score
(adjusted R squared ~ 0,22, P = 0,033)
As can be seen this is far from satisfactory as only 22% of the clinical
score is explained by this model. In addition the probability level is
high.
j The day 10 data did not yield a multiple regression model that was
satisfactory.
The day 30 model gave the following equation :-
Day 30 Clinical Score = 8,6 - 4,18 x Day 30 DV index score
- 0,36 x Day 30 segmental analysis score
(adjusted R squared = 0,86, P ::0,0000)
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An attempt was then made to determine whether day 1 SPECT scan
findings could be used as a prognostic index for day 30 clinical
scores. Limitations involved in this process werp the strict initial
selection of patients and the sn~ll sample size; which was further
compounded by clinical complicatiors.
Various multiple regression models were developed differing in the
patients excluded from statistical analysis on clinical grounds.
The most satisfactory prognostic model require; exclusion of the
mUltiple infarct patient only, and gave the following equation :-
Day 30 Clinical Score = 8,98 - 2,4 x Day 1 DV index + 0,08 x Day 1
area ratio score + 0,09 x Day 1 segmental
analysis score
(adjusted R squared = 0,49, D = 0,008)
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A. TECHNETIUM-99m HEXAME ~YL PROPYLENE AMINE OXIME
The major biological requirements for radiopharmaceuticals to perform as
reg10nal cerebral blood flow tracers are ;-
1) The ability to cross the intact blood brain barrier.
2) To accumulate in the brain ~uch that the regional dlstribut~on is
proportional to blood flow (51).
3) To remain witt- a fixed distribution within tile brain for a
sufficiently long 'ime to allow the acquisiti0n of data for
reconstruction of tomographic images (49).
i) Rndiopharmacology
lhe d,l diasterioisomer of Hexamethyl propylene amine oxime was the
tracer used in this study (HMPAO). It is lipophilic, neutral and of low
molecular weight and can thr'efore cross the normal blood brain
barrier. It complexes with Technetium-99m which has the ~deal
characteristics for the gamma Cdmera (monoenergetic gamma ray emissio~
of 141 KeV, physical half lifp.of 6 hours) and which can be obtained
from an 0n-site generator. Technetium-99m HMPAO has a long retention in
the brain with very slow redistribution, making SPECT scanning
possible. When complexed to Technetium-99m the compound is stable in
vitro for 30 minutes (49, 50, 51, 66).
See fig. 9
The first pass extraction by the brain is proportional to cerebral blood
flow. lhe unidirectional extraction into the brain is about 90% at
normal blood flow but decreases to 70% in very high flow areas (3D, 34,
65, 66, 67).
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Choksey et al speculate that although initial uptake of ).c-99m HMPAO
is related to regional cerebral blood flow, the absolute levels retained
in the brr1in lire dependant on other parameters which require
clarification, and that where abnormal uncoupling with metabolism occurs
HMPAO uptake must be interpreted with care (68).
An average brain activity of 2,1 - 7% of the injected dose is seen at
one minute after injaction. There is initial rapid blood clearance with
15% of the injected dose remaining in the blood at 5 minutes (10% at 1
hour. 4% at 24 hours). 10 - 15% of the cerebral activity washes out by
~ minutes, and then remains constant from 15 minutes to 8 hours. Fixed
regional distribution in the brain is required for 20 to 30 minutes for
SP~CT scanning. 86% of the initial activity is retained at 24 hours.
(49, 65, 6ij, 69, 70, 71, 72, 73).
Once in the brain there is slow conversion of the primary lipophilic
complex to a less lipophilic complex to permit retention in the brain.
Conversion in the human brain is fast, having a conversion half-life of
about 0,8 minutes. (67,68,74).
Costa at al found that HMPAO appears mainly in the organelles of the
cell (>55P,i) with a higher uptake seen in neurcna l > • c le i than in glial
nuclei in the rat brain (34, 63, 72).
Retention in the brain is determined by clearance of the lipophilic
portion by the blood and by conversion to the hydrophilic form. In the
brain as a whole, about 50% of the lipophilic fraction is permanently
retained in tl brain ~ubstance. Lear et a1 have suggested that only
half of the Tc-g9m HMPAO is aVdilable for exchange per pass, possibly
because of temporary localization in red cells or other blood
~ 43 M
constituents, or due to PP1sible conversion to a n~l~cerebrophilic ~
compound (67, 75). Andersen suggests that only a fraction of the
arterial radioactivity can be consider~d as brain input, as conversion
to the hydrophilic form is rapid in the blood (67). Neirinckx et al
suggested that the cellJlar uptake of HMPAO may be related to the tissue
glutathione content and that uptake may, therefore, be related to the
local metabolic rate (76). El-shirbiny in 1989 has found, however, that
only the uptake of HMPAO in the liver is related to glutathione content
in the cell (not brain uptake) (69),
The rest of the activity is widely distrlbuted in skeletal muscle and
soft tissue, especially subcutaneous fat. There may be slight uptake in
the thyroid «1%), lacrimal glands «1%), nasal and oral mucosa, gastric
mUCISB, and the skin (possibly in the sebaceous glands) (49, 65, 66,
71).
See Fig. 10.
Lung uptake of 12~13% of the injected dose may be seen but appears to
occur only in smokers. This uptake is seen in the first hour
pust.injection, then falls rapidly. The myocardium show 2% of the
activity (65).
The urinary tract is the main route of excretion with 37-40% of the
injected dose being excreted via the urine over 48 hours (66, 70, 71).
30% of the injected dose is found in the gastro-intestinal tract soon
after injection, of which half is excreted over 48 hours (i.e. 15% of
the injected dose). The liver extracts 13~15% which is excreted by the
hepatobiliary tract. The trqcer appears rapidly in the gallbladder and
intestine (49, 66, 70).
~ 44 •
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Radiation doses are well below acceptable levels (49, 66).
See fig. 11.
ii) Normal Images
The images obtained are blood flow maps which supply information on the
regional distriuution of blood flow. They are comparable to images
obtained with Iodine-123 iodoamphetamine and have the same distribution
as Xenon-133 flow maps (21, 33, 66, 67, 71).
There is good differentiation between white and grey matter, there being
greater uptake in grey matter. Uptake ratios for grey:white matter have
variously been reported as 1,12 - 1,96. Grey matter is composed mainly
of cellular structures, whilst white matter is mainly fibres and some
oligodendroglial cells (33, 34, 65, 66, 71).
Uptake is seen along the convexities of the hemispheres and along the
interhemispheric fissure, with greater uptake seen 'inthe basal ganglia
and cere.iolIum refit:,·tingthe greater blood flow in these areas (33, 50,
68). The periventricular space may appear larger than expected due to
the relative lesser uptake seen in the wbite matter surrounding the
ventricles (33, 50, 70). The caudate nucleus and thalamus are well
demonstrated but smaller structures are not resolved (70).
iii) Images seen in Acute Cerebral Infarction
Tc-99m HMPAO SPECr scans are particularly useful in the first 48 hours
after an acute infarction The SPECT scan shows physiological changes
whereas CT scans demonstrate structural changes (which are in fact the
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Fig. 11 RADIATION ABSORBED DOSES TO HUMANS
(~ef 49)
Target organ Absorbed radiation dose
(mGy per 500 MBq)
Testes
34.7
27.3
18.5
15.0
13.7
8.9
7.8
5.9
5.4
3.8
3.2
0.6
2.1
Lachrymal glands
Gall bladder wall
Kidney
Thyroid
Upper large intestine t'Jall
Liver
Small intestine wall
l.ower large Intestine wall
U"inary bladder \'1al1
Brain
OVaries
Whole body
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end result of a stroke) (14). This fact is demonstrated in this
stildy as on day 1 only 42% of CT scans were positive as compared to 84%
0, ~PECT scans. By day 10 the percentsge positive scans was the same.
HMPAO shows a central area ~f infarction (demonstrated by CT scan) with
a surrounding area of ischaemic but viable tissue (so~called ischaemic
penumbra), which is not seen on CT scan (14, 23, 77, 78). Perfusion
defects are initially larger than that seen on CT scanning. The
discrepancy in the size of the lesion on CT and SPECT scans will become
Jess obvious or disappear when surrounding temporary damage turns into
permanent tissue changes (14, 78). The peri-infarct area is probably an
area of de·fferentated neurons with decreased metabolism. Histologically
there is only a narrow transitional zone between ischaemic and viable
tissue (24, 78). In 104 patients studied in a multicentre trial, those
with chronic lesions showed the same defect as CT scans, whilst those
with acute strokes showed areas of decreased perfusion Jreater than the
low density areas s~en on CT scan (66). In 5 of 9 patients, Garret et
a1 found the area of hypoperfusion to be more extensive on HMPAO SPECT
scans than on CT scans or on MRI with the remaining 4 patients showin0
correspondi~g results with CT and MRI (18).
Imaging of established cerebral infarction with Xenon~133 and Pl.
studies show that the infarcted area is associated with low blood flow
as well as low m~tabolism (58). The estimated lower limit of blood flow
for cellular viability is 10-12 ml/lOOg/min and hypoperfusion must last
for at least 15 minutes to produce infarction (23). A flow of 12·18
ml/l00g/min can produce ischaemia with reversible failure of neuronal
activity without infarction (79). Permanent neurological del '~it may
depend on the function of collateral circulation. Collaterally perfused
araas are usually posterior and superior to the infarct, and are low
flQW areas with collateral circulation distal to the occlusion. These
areas may modify the H~PAO scan picture. On Xenon~133 scans a
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hyperaemic area may be seen anterior to the infarct,
queried whether this is normal brain tissue or not (23).
a~ it +s
The ischaemic penumbra is viable but non-functional tissue located
adjacent to an ischaemic infarct (23), and is not differentiated from
infarcted tissue on HMPAO scans (14). Cerebral arterial occlusion may
caUS0 differing degrees of tissue damage depending on the amount of
collateral blood supply to the ischaemic tissue.
The smallest cold spherical volume detectable on SPECT scanning is about
1 ml, and the smallest volume from which cerebral blood flow/cerebral
blood volume ratios can be derived is 15 ml (30). Areas of increased
and decreased flow may be demonstrated but uptake no longer correlates
with flow above 150-200 ml/lOOg/min (3D, 34). In lesions with regional
hypoperfusion of 10-20% less than the non-affected area, reduced
cerebral perfusion may not be clearly seen. Imaging of mild ischaemia
may therefore be of limited value (80).
Lacunar infarcts are very small infarctions in deep brain structures,
and of low density on CT scan (which may be of normal appearance) (7,
53). Van Royen in 1987 after studying 100 stroke patients, found
difficulty in localizing lacunar infarcts with Thalliurn-201 DOC and
Iodine-123 iodoamphetamin~ (35). However, 1 patient in our trial with a
lacunar infarct on CT scan «1,5cm lesion with no cortical involvement)
(81) was demonstrated with HMPAO both visually and semi-quantitatively.
B. LUXURY P,~RFUSION
Regional cerebral perfusion is regulated in part by the local metabolic
needs of the brain. An inappropriate vascular dilatation c~curs in
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acute stroke due to loss of the normal autoregulatory mechanisms
(82). Hyperperfusion has been defined as an overabundant cerebral blood
flow as compared with metabolic needs (77). Late luxury perfusion, seen
at 2 to 3 weeks post infarction has been attributed to focal
vasodilatation, loss of autoregulation and new capillary formation. The
pathophysiological basis for contrast enhancement on CT scanning is not
clear. Possible explanations are luxury perfusion, destruction of the
blood-brain barrier and new capillary growth (56, 77,83).
So-called luxury perfusion (hyperaemic infarction) is well detected on
Tc-99m HMPAO scans as an area of increased isotope uptake of greater
intensity than the opposite normal side. In this study, 7 of 18
patients (38,9%) scanned to day 10 showed 'luxury' perfusion or contrast
enhancement on CT scanning, and 5 patients (27,8%) demonstrated this
phenomenon on SPECT scanning.
Holmes et al reported luxury perfusion demonstration with Tc-99m HMPAO
in 7 pa~ients (84), while Van Royen et al demonstrated 'hot spots' in
some patients in the second week post-infarct using Thalliumu201 DOC,
but observed that this area seemed to correspond to the area of damaged
blood-brdin barrier (35). Raynaud et al found 5 of 27 patients to
demonstrate luxury perfusion on Iodine-123 IMP scanning (77).
C. CROSSED CEREBELLAR DIASCHISIS
Crossed cerebellar diaschisis or hypometab01ism has been reported in
approximately 50% of stroke patients. It is most prominent in large
lesions involving two or three cerebral lobes or after small lesions
destroying the internal capsule at basal ganglia level. Some metabolic
depression may also be seen in the ipsilateral cerebellar hemisphere,
although less severe (26, 28).
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Holmes et al found post-infarction contralateral cerebr.llar
hypoperfusion to be commonly seen in the recent stroke pat ie I;,
especially if the infarct was extensive and involved multiple
branches of the middle cerebral artery. They did not, however,
report this to be a common finding in chronic infarcts (84).
Graveline et a1 found 26 of 27 patients with motor lesions to have
crossed cerebellar diaschisis when studied with Tc-99m HMPAO from 5
days to 2 weeks after the acute stroke event. 15 of 15 patients with
non-motor lesions did not show significant cerebellar asymmetry (85).
In our study 72% of patients showed crossed cerebellar diaschisis
.i.e. a count density difference of more than 10 countj!o" al in a
small cerebellar region of interest as compared to the ip~flateral
cerebellar count density). Costa et al ha\e reported a normal right
to left cerebellum ratio as being 0,95 - 1,05 (63).
D. SEMI-QUANTITATION
Initial Tc-99m HMPAO uptake generally reflects local cerebral blood
flow, although in conditions of high flow ab~!e 150-200 ml/g/min,
retent ton of HMPAO is non-l inear (3D, 34). Absolute blood flow
quantitation is complicated by :-
1. Probable rapid conversion to a non-lipophilic compound.
2. Blood cell binding of the radiopharmaceutical.
3. Non-instant,neous cerebral trapping (86).
4. Initial back diffusion of the diffusible tracer from brain to
blood (87).
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Isotope retention is the result of initial uptake and subsequent
retention. Initial uptake is related to -
1. The amount of free tracer in the blood.
2. Blood flow.
3. Transit time through the cerebral capiliary bed (68).
Retention depends on :-
1. The rate of intracellular conversion to l non-diffusible form.
2. Outward diffusion of the un~onverted form (68).
Due to the difficulty in absolute flow quantitation with Tc-99m HMPAO
(68), several methods of semi-quantificatlon of regional cerebral blood
flow have been attempted. The methods used in this thesis are five
different kinds of semi-quantitation To validate these methods,
comparison to a "gold standard" such as PET scanning is indicated but is
both costly and difficult. For practical usage, a comparison to
clinical scoring of neurological deficit is required.
As expected, the site of Lne perfusion defect on SPECT scan images
agreed with ~linical signs and symptoms in our study. There was no
correlation betlveen clinical Gnd semi-quantitative scor~ changes over
the 30 day trial period (range of correlation coefficients = 0,08 -
0,19). Statistically it was found that actual individual
semi-quantitative methods did not always correlate with the clinical
score at that time. This seemed to indicate the necessity of a multiple
regression model. The best correlation was seen 0n day 30 using the
multiple regression model described in Chapter 4, where 86% of the
clinical score was explained by the ~odel, and where both the defect
volume index and the thirty degree segmental analYSis score (the least
observer dependant m' thad) were of importance.
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~ome technical and physiological drawbacks to semi-quantification have
becoma apparent, which may result in non-correlation of
semi·quantitative values with clinical scores.
1. In all the methods except the thirty degree segmental analysis, a
degree 0f observer experience was required ~o locate the exact
site and outline of the lesion and region of interest used f(~
day 1 and subsequent sans. Region of interest count d!nsitits
may vary slightly depending 0;1 the exact locatiou of the ROI.
This problem could be alleviated somewhn':: by having an automatic
edge detection of the hypoperfused area with & threshold
measurement. Mountz et al in 1989 defined lesion margins where
u~take values (counts/pixel) increased to within 10% of those in
the contralateral region of the uninvolved hernispher3, as
determined by moving a horizont.al profile through tha portion of
brbin containing the lesion (8D). This lesion reb·~ ~f interest
was mirrored on the contralateral hemisphere.
2. All the semi-quantitative methods used, except the defect volume
index and area ratio method, require comparison of the lesion to
an assumed normal area.
Intraindividual variation of meal) hemispheric blood flow was
reported as O,3~6 .±. 15% by Podreka (60). This implies that the
assumed nG;-m~1 cerebral hemisphere blood tlow rna.'!not remain a
constant during a trial period for serial scan comparison.
The assumed normal hemispheric blood flow may be depressed by
variable amounts in acute stroke patients, which may be due to
transcallosal diaschisis (26). The contralateral cerebral blood
flow has been reported as being significantly decreased in 56%
of patients (89). Should this depression of contralateral blood
flow not remain constant throughout the trial period,
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semi-quantHat; ve measurenrent comper t sons wou 1d be inaccurate.
3. Langen et a1 have sugp~sted that a lesion to cerebellum ratio is
a superior method of semi~quantitdtion as the contralateral
assumed nurmal hemisphere contains variable amounts of grey and
white matter and count Mensities in a region of interest may vary
from area to area (56). The cerebelIu.i represents a homogenous
reference region.
The cerebellar hemisphere with the highest counts should be used
if crossed cerebellar diaschici~ is present, with the iame
cerebellar hemisphere being used in subsequent scans, for the
lesion to cerebellar count density ratio method.
However, a norMal right to left cerebellar ratio can range from
0,95 - 1,05 which is a va;'iationof 10% (63). A difference of
more than 10% ;s required before crossed cerebellar diaschisis
can be determined. This variation in uptake could also affect
serial measurements when mild strokes are imaged.
4. The reference region cerebral blood flow may be altered by
distant functional depression of regional cerebral blood flow
(transcal'losal diaschisis), occult structural disease or systemic
determinants of regional cerebral blood flow. If contralateral
values used as normal reference paints were already low, the
decrease in the infarcted hemisphere would be less marked (89).
5. Patients with severe bilateral flow decrease may still be
identified as normal (89) as was ~he case in the multiple infarct
patient in this study.
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6. For correlation with clinical scoring, the clinical score must
accurately reflect the type of infarction present. For example,
the semi-quantitative values did not agree with the clinical
score for the patient with the posterior cerebral artery
territory infarct. Posterior cerebral artery territory infarcts
are not fully ~epresented on the Canadian neurologic rating
scale. It has been suggested that two types of scores could be
used to determine stroke severity, and may be different at entry
to the trial from outcome of the trial (11). For example,
inltial severity scored with regard to prognostic factors at
entry, and outcome scores depending on functional performance as
well as neurologic examination.
A small infarct located in the internal capsule may produce
striking clinical deficit (15) but be repre$ented only as a mi1d
semi-quantitative score in our observation.
7. Nishizawa found that in lesions with regional hypoperfusion of
only 10 - 20% less than the non-affected area, decreased
cerebral perfusion may not be clearly seen (BO). Differences of
less than 20% were seen in our study, in 11 of 19 patients with
the lesion to normal count density method, and in 14 of 19
patients using the thirty degree segmental analysis method, both
of which are side to side comparisons.
Contrast between high and low flow areas seen with HMPAO is
less than expected due to preferential washout from high flow
areas (67). This may affect semi-quantitative serial
measurements if washout differences do not remain constant.
8. Clinical changes such as the presence of luxury perfusion, the
appearance and resolution of cerebral oedema and the development
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of collateral flow (63) will all influence the correlation
between clinical scores and semi-quantitative methods. Better
correlation may be seen when the clinical picture has completely
settled down, as indicated in our study by the improved
correlation at thirty days.
A varying degree of involvement of clinically silent regions of
the brain (16) may also cause problems when relating
semi-quantitative scores to clinical scores.
9. Technical problems may include errors in head position, errors
in attenuation correction (89), lesion margin detection and
region of interest positioning.
10. Hayashida at a1 have reported the problem of masking reduced
cerebral blood flow by an increase in regional cerebral blood
volume in early HMPAO images in region of mild cerebral
ischaemia. Leakage of HMPAO is seen in the late image at 5 hours
in these regions and the filling out phenomenon was attributed
to a significant reduction of blood activity of the
radiopharmaceutical. This phenomenon was observed in 7 of 21
Cases studied with cerebrovascular disease (90). The blood pool
image may interfere with the detection of true regional cerebral
perfusion deficits on early images.
A decrease in cerebral blood flow (CBF) can initially be
prevented physiologically by increased cerebral blood volume
(CBV) (91). This cerebral vascular reserve may affect initial
semi-quantitative measurements.
reserve imaging using HMPAO and
pyrophosphate was found to
cerebrovascular disease by 48% as
Flow-volume-cerebral vascular
Technetium pertechnetate with
increase sensitlvity in
compared to mere cerebral flow
imaging (59, 91). A decrease in cerebral perfusion pressure may
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be compensated for by an initial increase in cerebral blood
volume. The smallest v~lume from which accurate C3F/CBV ratios
can be derived is abcut 15 ml. Knapp et al found that the CBF of
affected territories was 85 ± 19% when related to the
nonsymptomatic contr-alatera l side (100%), using 1-123
iodoamphetamine. CBF/CBV ratios were 60 ± 32% showing a more
sensitive approach to cerebrovascular disease (61).
The above problems are highlighted by the fact that on statistical
analysis of our data, a correlation between semi-quantitative analysis
scores and clinical scores was only of significance once the data had
been cleaned", that is, when multiple infa~cts, posterior infarcts and
restrokes were excluded. Correlation was still poor on day 10 which may
be due to the presence of luxury perfusion or possibly due to a.state of
clinical flux as described above.
Misleading results can occur if intra-individual standardization is used
in patients with cerebrovascular disease. Inter-subject comparison of
semi-quantitative regional cerebral blood flow values may, however, be
difficult due to physiologic variability of regional cerebral blood
flow, as has been seen with PET scanning quantification (89).
Changes from day 1 to day 30 on semi-quantitative analysis of SPECT
scans reflected clinical improvement or deterioration poorly in this
study (ranging from 27,8% of cases in the thirty degree segmental
analysis method to 50% in the lesion to cerebellar count density ratio
method). Changes in scan appearance and cllnical improvement may
correlate better when follow up at one year is performed or where a
larger study sample is possible.
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Smith et al found some correlation between the sizt and site of
perfusion deficits on HMPAO scans and clinical signs ir.the first 3 days
after a stroke lno correlation factor given). However, in this study,
scans appear to have been visually assessed in a wide range of
infarction sites. When 12 patients were again asses3ed at day 14, the
clinical progress was not accurately reflected by changes on the scan
(92).
Yeh found that complete or partial clinical remission does not a1ways
accompany resolution of a perfusion defect on HMPAO scans when scanned
on days 1, 14 and 21. The authors concluded, however, that serial scans
provided an objective visual assessment of perfusion changes (93).
E. PROGNOSTIC VALUE OF SCORES
Simple correlations between day 1 SPECr semi-quantitative ~cores and day
30 clinical scores were not satisfactory. However, a multiple
regression model utiliz1ng the day 1 Defect Volume index, day 1 area
ratio method score and the dby 1 thirty degree segmental analysis score
was correlated with day 30 clinical scores (adjusted R squared = 0,48, P
= 0,008). It may be that with a larger sample size or longer follow up
of patients this predictive equation could be found to torrelate with
greater-accuracy. Individual method correlations may also improve.
Clinically, poor prognostic features that can be detected soon after
stroke onset are :-
Impaired consciousness.
Dense hemiplegia.
Failure of conjugate ocular gaze towards the side of limb
weakness.
Overt unconsciousness
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Bilateral plantar response.
High haematocrit at hospital admission.
Underlying medical complications, especially the co-existence of
cardiac disease and renal 'insufficiency.
These signs Lsually indicate infarction of the whole of a middle
cerebral artery territory, and these patients are prone to develop
severe cerebral oedema. (16, 24, 52, 94, 95)
The outcome of a major cerebrovascular event is difficult to establish
and aepends on the type, extent and localization of the lesion (63) as
well as the clinical state of the patient (degree of neurological
deficit) (52).
Several authors have found that outcome can be predicted from Clinical
scoring. The Canadian neurological score used in this study is related
more to actual neurological deficit than to daily living activities or
rehabilitative factors. However, there was a good correlation between
day 1 and day 30 clinical scores (r = 0,94, P = 0,00). The Scandir.1vian
Stroke study group found that neurologic scores at entry to the
multicentre haemodilution trial strongly predicted mortality and
neurologic performance at 3 months using a a - 48 point scale (including
activities of daily living) (94).
Using a prognostic clinical score of 100 points in 200 unselected
patients with a first episode of acute cerebrovascular disease, Britton
correctly predicted mortality and functional outcome in 60%. It is
suggested that the clinical state of the patient is more important for
the immediate prognosis than the nature of cerebral damage, and that a
subjective evaluation of the overall clinical state as well as
neurologic scoring is required (52).
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Prescott
predict
et al, using a multiple regression formula, could clinically
independence or functional outcome, which is the optimal
end-point in stroke trials, in 75% of cases in week 4 post-infarction,
in r.tients ente~ed in a rehabilitation program. This may be of valu~
in determining those with little chance of responding to rehabilitation
(6) •
Frithz et al, in 344 patients, found that the level of consciousness and
a calculated score based on neurological symptoms on admission hdd the
highest predictive value. Using this score it was possible to predict
the outcome in about 85% (95).
The above reports indicate that there cire many factors of possible
importance for stroke outcome and that the situation calls for a
multivariate analysis of prognostic feat~res. The same was found in our
study for semi-quantitative analysis of prognostic features.
It is important to emphasize that the clinical scoring in the quoted
papers, as occurred in our pilot study, was performed by specialised
units with exper icnced observers.
routine clinical setting.
This might not be the case in a
Signs on CT scan carrying a bad prognosis in connection with major
stroke symptoms are -
Mass effect.
Involvement of the internal capsule.
Right parietal lesions (rather than left sided lesions).
Dense middle cerebral artery sign in the first 24 hours (an
early warning of a large infarction, brain oedema and poor
prognosis).
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Large volume of~farction on CT scan.
(16, 96, 97)
Va1dimarsson et a1 found that a pos'itive correlation existed between the
state of patients on admission and t~e lesion volume on CT scanning (in
69 patients), but that the lesion volume was of low prognostic
significance when initial disability was slight ").
In our study, it was found that a multi-factorial equation is required
to predict Day 30 clinical scores from Day 1 SPECT semi-quantitative
scores using HMPAO.
Lee et a1 stud;PG 16 patients with acute cerebral infarction of middle
cerebral artery distribution with I-131 iodoamphetamine and PET scanning
to assess the predictive value of the perfusion defect size and lesion
count density, with respect to clinical outcome. Scans were performed
in the first week with a mean follow up of 19,4 months (much longer than
in our study). Lesion size and decreased count density correlated well
with presenting clinical severity but not with outcome It is suggested
that lack of a prognostic index may be because areas of ischaemia are
also being imaged which do not necessari1y result in cell death (62).
This may also be a factor with HMPAO.
Launes et al using HMPAO to define a defect volume index (as used in
this study) found a significant correlation between the clinical outcome
and the Defect Volume index. This was best seen in middle cp,rebral
artery infarcts, with no prognostic correlation seen in posterior
cerebral artelY infarcts. 64 patients were included in the study, but
were initially scanned between 1 to 46 days after stroke onset with
clinical follow up varying from 6 - 412 days (24). Although the DV
index in our study was found to be an important factor in the multiple
- 61 -
..
regression model defined for prediction of day 30 clinical scores,
simp1e correlation of the day 1 index with the day 30 clinical picture
was not satisfactory. This may be due to the smaller sample size,
shorter follow up and more rigid timing of scans in our study.
Costa reported a method of quantifying wAshout of Tc-99m HMPAO using a
ratio of abnormal brain to cerebellar activity on 15 minu~e and 5 hour
scans. The washout activity was much higher in the abnormal area as
compared to other regions of the brain. Th:s washed out activity was
probably from the capillary bed, as HMPAO in the brain cells is
retained. This washout could, ther~fore, agree with an area of
increased 'vascular reservel with high blood volume. Incomplete washout
would indicate the presence of viable brain tissue. It is suggested
that a prognostic index may be devised if this method is used (63),
Semi-quantitative methods evaluating the ischaemic penumbra (viable but
non-functional tissue adjacent to the ischaemic infarct (23)) may have
more prognostic and therapeutic value than simple determinations of the
perfusion defect on HMPAO imaging. Restoration of blood flow to such
areas may restore normal function and faci1itate recovery. Wise et a1
using PET scanning to determine oxygen extraction following acute
strokes found that the ~eriod after the onset of the stroke when tissue
damage remains potentially reversible is between 24 - 48 hours (22).
With this aim in mind, Mountz et al found that with regression analysis,
complete or near complete recovery at one year was seen in ~atients who
at initial evaluation had a HMPAO SPECT lesion that was 3,9 ± 0,9 times
greater than the CT scan lesion indicating a large area of ischaemic
penumbra. Patients with some or no recovery had a lesion which was 1,4
± 0,3 times larger on CT scan than on SPECT scan (i.e. almost the same
size defect). Comparative analysis of CT and HMPAO SPEeT scans are
useful in prognosis (88, 98). A high ratio between the functional
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defect seen on SrF.CT scan and the anatomical defect seen on CT scan
indicates viable but dysf~~ctional tissue with a capacity for
restoration and therefore better clinical recovery. The larger the log
(SPECT divided by CT) re~ult the greater the likelihood of good clinical
outcome.
RaynaLd et al using 1-123 IMP found two differing areas of infarction; a
centrul area of persistent decrease of IMP uptake and hypoden&ity on CT
scan, and a peripheral area with a filling in of IMP at 5 hours and no
CAT hypodensity. Neurological status correlated only with peripheral
area volume (not central area volume) (78).
Moretti found that the size of redistribution of 1-123 IMP between early
(1 hour) and delayed (4 hour) scans s~gnificantly correlated with the
three month clinical outcome, whereas the value of hypoactivity on early
SPECT only, did not. The higher the redistribution amplitude, the
better the clinical outcome (99).
Curre.lt literature ana Jr observations appears that the long-term
prosnosis of stroke patients depends mainly on the degree of ischaemic
~amage done to the brain tissue (100). Partial ischaemia may result in
the loss of normal neuro~al function without inducing the changes that
result in irreversible damage for some hours (22).
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CHAPTER 6
CONCLUSION
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CONCLUSION
In this study t.refollowing trends could be identified:-
1. SPECT cerebral perfusion studies using iechnetium-g9m HMPAO are
of value 1n day 1, for the early localization or ~cu~z ischaemic
cerebral infarction. Reversibly damaged brain tissue may be
identified in conjunction with CT scanning, by defining the
ischaemic penumbra.
SPECT s~an images represent functional changes in blood supply
and their use may he1p the physician to better under~tand the
pathophysiologic basis of brain infarction.
2a. The semi-quantitative SPECT scores correlated well with each
other on days 1 ~nd 30. Poor correlation is seen on day ten.
b. Semi-quantitative scor~ changes from day 1 to day 30 did not
agree with clinical scor~ chang~s. This may not be true for long
term follow-up scans.
c. No correlation between semiq!Jantit'ative method scores and
clinical scores was seen on day 1. On day 30, only the area
ratio method showed significant correlation with day 30 clinical
scoring.
d. Multiple regression models are required for comparison of
semi-quantitative and clinical scores. In our study, multiple
regression analysis was only satisfactory on day 30.
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3. A multiple regression model can be devised to predict outcome at, ~
day 30, using the day 1 Defect Volume index, day 1 area ratio
score and day 1 segmental analysis score.
This suggests that d better prognostic correlation may be
achieved with a larger sample size and longer follow up period.
A trend ;s shown that SPEeT scans at day 1 are valuable in the
prediction of the day 30 clinical score.
- 66 -
APPENDIX
- 67 -
PERCENTAGE POSITIVE SCANS SEEN WITH EACH
SEMI-QUANTITATIVE METHOD AND WITH VISUAL
METHOD DAY 1 DAY 10
I
DAY 30
Defect Volume Index 89,50/0 88,9% I 78,6%I
tSide to side count density 89,5% 88,9% 78,6~~compar-ison
Percentage of cerebellar 89,5% 83,3% 78,6"1Q
count density
Segmental analysis 63% 66,7% 64,3%
Area ratio method 89,5'10 88,9% 78,6%
Visual analysis 84% 83,3"10 78,6"10
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